Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

PHASE2UnknownINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

April 30, 2023

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
BIOLOGICAL

Expanded Activated Lymphocytes (EAL)

12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.

PROCEDURE

transarterial chemoembolization (TACE)

After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Immunotech Applied Science Ltd.

INDUSTRY

lead

Chinese PLA General Hospital

OTHER

NCT05213637 - Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection | Biotech Hunter | Biotech Hunter